Nanomedicine News

RSS

Ignyta Initiates RXDX-107 Phase 1/1b Clinical Trial of Alkyl Ester of Bendamustine Encapsulated in HSA to Form Nanoparticles

Ignyta, Inc., a precision oncology biotechnology company, announced today the initiation of the company’s Phase 1/1b clinical trial of RXDX-107, its next generation alkyl ester of bendamustine encapsulated in human serum albumin (HSA) to form nanoparticles.

21 Sep 2015

Injecting Gold Nanoparticles in Mammary Tissue Enhances Imaging of Early Signs of Breast Cancer

Detecting breast cancer in women with dense mammary tissues could become more reliable with a new mammogram procedure that researchers have now tested in pre-clinical studies of mice. In their report in the journal ACS Nano, they describe injecting gold nanoparticles in mammary tissue to enhance the imaging of early signs of breast cancer.

From American Chemical Society 18 Sep 2015

FDA Accepts EnGeneIC’s IND for EGFR-Targeted Nanocells Carrying Doxorubicin to Treat Recurrent Glioma

EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application for using (EGFR)-EDVs loaded with doxorubicin (dox) in patients with recurrent glioma.

18 Sep 2015

Coated Silica Nanoparticles Could be used for Restorative Treatment of Sensitive Teeth

Researchers at the University of Birmingham have shown how the development of coated silica nanoparticles could be used in restorative treatment of sensitive teeth and preventing the onset of tooth decay.

18 Sep 2015

Platelet-Mimicking Nanoparticles Could Effectively Deliver Drugs to Targeted Sites

Nanoparticles disguised as human platelets could greatly enhance the healing power of drug treatments for cardiovascular disease and systemic bacterial infections. These platelet-mimicking nanoparticles, developed by engineers at the University of California, San Diego, are capable of delivering drugs to targeted sites in the body -- particularly injured blood vessels, as well as organs infected by harmful bacteria.

18 Sep 2015

NSF Awards UCLA $1 Million Grant for Quantification and Automated Characterization of Nanoparticles

Researchers at the UCLA Henry Samueli School of Engineering and Applied Science and California NanoSystems Institute (CNSI) have won a $1 million, three-year grant from the National Science Foundation for on-site and ubiquitous quantification and automated characterization of nanoparticles found in homes, workplaces and the environment.

From University of California, Los Angeles 18 Sep 2015

Novel Technique for Real-Time Observation of Bloodstream Protein Interactions with Nanoparticles

Technique developed by NUS-led team provides more precise understanding of how proteins in the bloodstream bind to nanoparticles, paving the way for better design of nanomedicines

18 Sep 2015

Researchers Secure €3.3 Million Funding to Develop Enhanced Nanoparticle Treatment Programme for Pancreatic Cancer

Researchers at the University at Buffalo, Dublin City University and Queen’s University Belfast have secured over €3.3 million to develop an enhanced treatment programme for pancreatic cancer, the fourth leading cause of cancer deaths in the world.

16 Sep 2015

Onxeo Seeks Patent for Livatag Liver Cancer Orphan Oncology Product

Onxeo S.A., an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent application has been filed in the US and Europe and will be expanded to include other regions, including the Asian territories, under the patent review procedure. If granted, this patent would protect Livatag® until 2036.

16 Sep 2015

Novavax RSV F-Protein Recombinant Nanoparticle Vaccine Candidate Highly Immunogenic in Preclinical Maternal Immunization Model

Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.

From Novavax Inc. 16 Sep 2015

Nanomedicine News

Ignyta Initiates RXDX-107 Phase 1/1b Clinical Trial of Alkyl Ester of Bendamustine Encapsulated in HSA to Form Nanoparticles

Injecting Gold Nanoparticles in Mammary Tissue Enhances Imaging of Early Signs of Breast Cancer

FDA Accepts EnGeneIC’s IND for EGFR-Targeted Nanocells Carrying Doxorubicin to Treat Recurrent Glioma

Coated Silica Nanoparticles Could be used for Restorative Treatment of Sensitive Teeth

Platelet-Mimicking Nanoparticles Could Effectively Deliver Drugs to Targeted Sites

NSF Awards UCLA $1 Million Grant for Quantification and Automated Characterization of Nanoparticles

Novel Technique for Real-Time Observation of Bloodstream Protein Interactions with Nanoparticles

Researchers Secure €3.3 Million Funding to Develop Enhanced Nanoparticle Treatment Programme for Pancreatic Cancer

Onxeo Seeks Patent for Livatag Liver Cancer Orphan Oncology Product

Novavax RSV F-Protein Recombinant Nanoparticle Vaccine Candidate Highly Immunogenic in Preclinical Maternal Immunization Model

Engineered Nanoparticles Break Heavy-Oil Emulsions In One Hour

DNA Origami Pushes Nanotechnology Toward Smarter Medicine and Electronics

Vistec Showcases Momentum in E-Beam Lithography for Photonics and Advanced Semiconductor Applications at EMLC 2026

Nanoparticle Prime Editing Corrects Metabolic Disease Mutation in Mice

Nature’s Nanotech Warriors Could Clean Up Toxic Metal Pollution

How First Graphene is Turning Potential into a Reality

Smarter, Faster Stability Testing: Improving Detergent and Cosmetic Formulation Development

Combining Flexibility and Automation in FIB-SEM for TEM Lamella Preparation

Featured Articles

Nanomaterials in 2026: Commercial Adoption in Medicine, Aerospace, and 3D Printing

Market Report: The Next Wave of Atomic Force Microscopy

Could Sodium-Ion Batteries Challenge Lithium, and What Role Does Nanotechnology Play?

Sponsored Content

Your Guide to Powder Bed-Based Additive Manufacturing and Powder Rheology

Graphene Layer Identification Using Raman Spectroscopy

How to Perform High-Strain-Rate Testing Using SEM Nanoindentation

Monitoring Dye–Protein Binding in Microliter Volumes